Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 179 cases were analyzed for the JAK2 mutation. Among them, cytogenetic data were available for 97 cases-45 of 106 JAK2+ and 52 of 73 JAK2-. The JAK2+ group showed a higher frequency of cytogenetic anomalies than the JAK2- group (23/45 [51%] vs 14/52 [27%]). Chromosome 9, chromosome 7, and 20q- were recurrent abnormalities in the JAK2+ group, whereas 13q- and trisomy 21 were common in the JAK2- group. In the JAK2+ group, chromosome 7 and complex cytogenetic abnormalities were associated with excess blasts/blastic transformation (P < .05), whereas no cases with 20q- underwent blastic transformation. Our results suggest that incorporation of JAK2 mutation testing and karyotyping allows for monitoring of disease progression with prognostic and therapeutic implications.

[1]  M. Cazzola,et al.  Myelodysplastic/myeloproliferative neoplasms. , 2011, Hematology. American Society of Hematology. Education Program.

[2]  F. Appelbaum,et al.  Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. , 2010, Blood.

[3]  A. Tefferi,et al.  International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. , 2010, Blood.

[4]  K. Sotlar,et al.  Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KIT D816V and JAK2 V617F , 2010 .

[5]  A. Tefferi,et al.  JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival , 2010, Leukemia.

[6]  H. Büller,et al.  Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. , 2009, Thrombosis research.

[7]  T. Haferlach,et al.  Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category , 2009, Annals of Hematology.

[8]  W. Chung,et al.  Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. , 2009, Leukemia research.

[9]  H. Kantarjian,et al.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. , 2009, Blood.

[10]  P. Guglielmelli,et al.  JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis , 2009, Haematologica.

[11]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Chevret,et al.  The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. , 2008, Blood.

[13]  A. Tefferi,et al.  Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates , 2008, European journal of haematology.

[14]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[15]  R. Mesa,et al.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.

[16]  K. Sotlar,et al.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. , 2008, The Journal of molecular diagnostics : JMD.

[17]  Paola Guglielmelli,et al.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.

[18]  A. Panani.  Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. , 2007, Cancer letters.

[19]  A. Tefferi,et al.  Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.

[20]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[21]  A. Bagg,et al.  Myeloproliferative Disorders and Myelodysplastic Syndromes , 2007 .

[22]  K. Strasser-Weippl,et al.  Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia , 2006, Cancer.

[23]  A. Tefferi,et al.  Cytogenetic Abnormalities in Essential Thrombocythemia: Prevalence and Prognostic Significance. , 2006 .

[24]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[25]  R. Kralovics,et al.  Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.

[26]  P. Brousset,et al.  Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation. , 2006, Human pathology.

[27]  C. Copie-Bergman,et al.  A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma , 2006, Leukemia.

[28]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[29]  M. Wadleigh,et al.  The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.

[30]  A. Gotoh,et al.  The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients , 2005, Leukemia.

[31]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[32]  A. Tefferi,et al.  Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia , 2005, Cancer.

[33]  M. Wadleigh,et al.  JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance , 2005, British journal of haematology.

[34]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[35]  M. Cazzola,et al.  Leukemic transformation of polycythemia vera , 2005, Cancer.

[36]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[37]  D. Gilliland,et al.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. , 2005, Mayo Clinic proceedings.

[38]  K. Strasser-Weippl,et al.  Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. , 2005, Blood.

[39]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[40]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[41]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[42]  W. Hiddemann,et al.  Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information , 2005, Annals of Hematology.

[43]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[44]  S. Serrano,et al.  Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients? , 2004, Cancer genetics and cytogenetics.

[45]  F. Solé,et al.  Incidence of trisomy 8 and 9, deletion of D13S319 and D20S108 loci and BCR/ABL translocation in non-treated essential thrombocythemia patients: an analysis of bone marrow cells using interphase fluorescence in situ hybridization. , 2003, Haematologica.

[46]  J. Richie.  Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site,- and histopathology-related differences--a Children's Cancer Group Study. , 2002, The Journal of urology.

[47]  R. Mesa,et al.  Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[48]  S. Geller,et al.  Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. , 1986, Seminars in hematology.

[49]  J. Rowley,et al.  The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis , 1985, Cancer.